Angelo Canonico, MD
Critical Care Medicine · Nashville, TNNPI 1407896749
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 752 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,730 and has fallen 99.3% since, to $19 in 2025. Among critical care medicine clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 752 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$2K
- AstraZeneca$2K
- GSK$2K
- Insmed, Inc.$1K
- Electromed, Inc.$804
- plus $5K from 30 others
Across 2 payments — averaging $8305.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$13K
- E.r. Squibb & Sons, L.L.C.$3K
What the payments were for
- Food & beverage$14,17297%
- Education$3703%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 117 | $2,170 |
| Boehringer Ingelheim | 102 | $2,122 |
| AstraZeneca | 79 | $1,642 |
| GSK | 120 | $1,558 |
| Insmed, Inc. | 48 | $1,183 |
| Electromed, Inc. | 35 | $804 |
| Grifols USA, LLC | 35 | $753 |
| United Therapeutics Corporation | 25 | $554 |
| Regeneron Healthcare Solutions, Inc. | 27 | $546 |
| Sanofi | 22 | $510 |
| Mylan Specialty L.p. | 25 | $459 |
| Merck | 15 | $333 |
| Pfizer | 21 | $322 |
| Amgen | 17 | $291 |
| Genentech USA, Inc. | 9 | $178 |
| Johnson & Johnson | 8 | $138 |
| Inari Medical, Inc. | 2 | $111 |
| Axsome Therapeutics, Inc. | 4 | $107 |
| Bayer | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Circassia Inc. | 4 | $69 |
| Sunovion Pharmaceuticals Inc. | 5 | $67 |
| Teva Pharmaceuticals USA, Inc. | 3 | $64 |
| Jazz Pharmaceuticals Inc. | 3 | $60 |
| Mallinckrodt Enterprises LLC | 2 | $51 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| Novartis | 3 | $45 |
| Pulmonx Corporation | 2 | $40 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Boston Scientific | 2 | $27 |
| Baxter Healthcare | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Philips North America LLC | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $17 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMBICORT$274
- BREZTRI$258
- FASENRA$142
- AIRSUPRA$142
- TEZSPIRE$142
- BREZTRI AEROSPHERE$132
- BEVESPI AEROSPHERE$132
How this compares
$14,542 in reported general payments places this provider in the 90th percentile of 141 critical care medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 39 | $513,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 416 | $328,045 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 127 | $96,276 |
| Breo ElliptaFluticasone/Vilanterol | 150 | $81,938 |
| Dupixent PenDupilumab | 13 | $48,213 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $22,913 |
| EliquisApixaban | 27 | $22,020 |
| Arnuity ElliptaFluticasone Furoate | 57 | $18,518 |
| Spiriva RespimatTiotropium Bromide | 26 | $13,669 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 67 | $12,674 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $11,447 |
| Qvar RedihalerBeclomethasone Dipropionate | 27 | $9,176 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 283 | $8,394 |
| BreynaBudesonide/Formoterol Fumarate | 48 | $8,097 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $6,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $2,122 | $549,62294 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $1,558 | $435,167634 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,642 | $107,723168 claims |
| PfizerEliquis | $322 | $22,02027 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $64 | $9,17627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 141 critical care medicine providers in Tennessee.
Other critical care medicine in Nashville
- Gordon BernardNashville$730K
- Todd RiceNashville$291K
- Jamie DeneauNashville$33K
- Ann GageNashville$22K
- Lorraine WareNashville$18K
- Shelton HarrellNashville$16K
- Joseph SchlesingerNashville$15K
- Erik HessNashville$14K
- Jonathan CaseyNashville$13K
- Eugene ElyNashville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.